Trade

with

ARIAD Pharmaceuticals Inc
(NASDAQ: ARIA)
AdChoices
5.79
+0.09
+1.58%
After Hours :
-
-
-

Open

5.75

Previous Close

5.70

Volume (Avg)

2.68M (7.42M)

Day's Range

5.54-5.79

52Wk Range

2.15-9.83

Market Cap.

1.07B

Dividend Rate ( Yield )

-

Beta

1.52

Shares Outstanding

187.01M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 45.56M

    • Net Income

    • -274.16M

    • Market Cap.

    • 1.07B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -504.79

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.52

    • Forward P/E

    • -7.88

    • Price/Sales

    • 21.69

    • Price/Book Value

    • 8.70

    • Price/Cash flow

    • -5.29

      • EBITDA

      • -269.43M

      • Return on Capital %

      • -53.25

      • Return on Equity %

      • -114.34

      • Return on Assets %

      • -53.25

      • Book Value/Share

      • 0.66

      • Shares Outstanding

      • 187.01M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 10.50

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.72

        • Cashflow Estimate

        • -0.58

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -13.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 45.11

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.87

            • 82.75

            • Pre-Tax Margin

            • -503.73

            • 39.38

            • Net Profit Margin

            • -504.79

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 95.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -8,317.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 2.42

              • 0.76

              • Current Ratio

              • 5.09

              • 2.92

              • Quick Ratio

              • 4.95

              • 2.35

              • Interest Coverage

              • -370.58

              • 38.02

              • Leverage Ratio

              • 4.01

              • 2.21

              • Book Value/Share

              • 0.66

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.36

                • 243.90

                • P/E Ratio 5-Year High

                • -19.11

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.28

                • 124.82

                • Price/Sales Ratio

                • 22.03

                • 9.29

                • Price/Book Value

                • 8.83

                • 8.39

                • Price/Cash Flow Ratio

                • -5.29

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -114.34

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -53.25

                    (-54.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -62.69

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 15.60

                  • 1.48

                  • Asset Turnover

                  • 0.11

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -273.57M
                  Operating Margin
                  -600.44
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.29
                  Ownership

                  Institutional Ownership

                  66.92%

                  Top 10 Institutions

                  41.09%

                  Mutual Fund Ownership

                  29.94%

                  Float

                  89.69%

                  5% / Insider Ownership

                  2.13%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    9,117,251

                  • 0.00

                  • 4.88

                  • Franklin Biotechnology Discovery

                  •  

                    3,387,100

                  • -5.23

                  • 1.81

                  • Vanguard Small Cap Index

                  •  

                    2,924,722

                  • -0.22

                  • 1.56

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,752,220

                  • 0.16

                  • 1.47

                  • SPDR® S&P Biotech ETF

                  •  

                    2,674,193

                  • -9.83

                  • 1.48

                  • iShares Russell 2000 (AU)

                  •  

                    2,491,501

                  • -1.81

                  • 1.38

                  • iShares Nasdaq Biotechnology

                  •  

                    2,430,937

                  • -0.24

                  • 1.35

                  • Pictet-Biotech

                  •  

                    2,010,831

                  • 0.07

                  • 1.10

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    1,975,871

                  • -2.04

                  • 1.06

                  • Fidelity® Independence Fund

                  •  

                    1,782,600

                  • 0.00

                  • 0.95

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    13,380,046

                  • 0.00%

                  • 7.16

                  • Sarissa Capital Management LP

                  •  

                    12,850,000

                  • +7.08%

                  • 6.87

                  • Vanguard Group, Inc.

                  •  

                    10,655,939

                  • +2.62%

                  • 5.70

                  • BlackRock Fund Advisors

                  •  

                    6,439,785

                  • +78.53%

                  • 3.45

                  • State Street Corp

                  •  

                    5,772,991

                  • +19.08%

                  • 3.09

                  • Franklin Advisers, Inc.

                  •  

                    5,038,427

                  • -2.24%

                  • 2.70

                  • Camber Capital Management LLC

                  •  

                    5,000,000

                  • +66.67%

                  • 2.68

                  • Renaissance Technologies Corp

                  •  

                    4,399,981

                  • +95.66%

                  • 2.35

                  • AQR Capital Management LLC

                  •  

                    3,882,830

                  • +320.44%

                  • 2.08

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling w...moreith small molecules. The Company’s first approved cancer medicine, Iclusig® (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be...more readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company’s competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.lessless

                  Key People

                  Dr. Harvey J. Berger,M.D.

                  Founder/CEO/Chairman of the Board/President/Director

                  Edward M. Fitzgerald

                  CFO/Chief Accounting Officer/Executive VP/Treasurer

                  Martin J. Duvall

                  Executive VP/Other Executive Officer

                  Dr. Athanase Lavidas,PhD

                  Director

                  Jay R. Lamarche

                  Director

                  • ARIAD Pharmaceuticals Inc

                  • 26 Landsdowne Street

                  • Cambridge, MA 02139-4234

                  • USA.Map

                  • Phone: +1 617 494-0400

                  • Fax: -

                  • ariad.com

                  Incorporated

                  1991

                  Employees

                  307

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: